This case targets the 2001 dialogue between Mytex Pharmaceuticals and the U.S. Food and Drug Administration (FDA). The results of the dialogue would determine the new label for Mytex's blockbuster drug for arthritis, Flaxil.
The Flaxil Label (B) case study solution
The dialogue is quite qualitative and differs from the typical cost negotiation with which students are familiar. Nevertheless, at position was $500 million in Flaxil sales and safety of millions of patients. The (B) case present the standpoint of a patient and her doctor as they reflect on the new information concerning Flaxil's threat profile.
PUBLICATION DATE: August 24, 2008 PRODUCT #: 909002-HCB-ENG
This is just an excerpt. This case is about LEADERSHIP & MANAGING PEOPLE
Related Case Solutions & Analyses:
Coach Knight and Coach K
Ganging up on Cancer: Integrative Research Centers at Dana-Farber Cancer Institute (B)
Managing the Layoff Process: France
Scoring a Deal: Valuing Outcomes in Multi-Issue Negotiations
The Cambodian National HIV/AIDS Program: Successful Scale-Up through Innovation
DISC (A) (Abridged)
Walden Woods
Managerial Duties and Business Law
Executive Women at Link.Com
Harassment at Work?
